Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by Bi- and trifunctional inhibitors of tumor-associated proteolytic systems

Biological Chemistry

Volumn 384, Issue 7, 2003, Pages 1097-1102

  Krol, Janna ^a   Kopitz, Charlotte ^a   Kirschenhofer, Angela ^a   Schmitt, Manfred ^a   Magdolen, Ulla ^a   Krüger, Achim ^a   Magdolen, Viktor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cysteine protease; Matrix metalloproteinase; Serine protease; Tumor invasion; Urokinase

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; CYSTATIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ENZYME INHIBITOR; PLASMID VECTOR; PROTEINASE; SERINE PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UROKINASE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEUM; PERITONEUM TUMOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; SOLID TUMOR; VECTOR CONTROL;

ANIMALS; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; ENDOPEPTIDASES; FEMALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLASMIDS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSFECTION;

ANIMALIA; GALLUS GALLUS; MUS MUSCULUS;

EID: 0042279173     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.122     Document Type: Article

References (28)

1. Andreasen, P.A., Egelund, R., and Peterson, H.H. (2000). The plasminogen activation system in tumor growth, invasion and metastasis. Cell. Mol. Life Sci. 57, 25-40.
2. Brand, K. (2002). Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr. Gene Ther. 2, 255-271.
3. Chang, C., and Werb, Z. (2001). The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11, 37-43.
4. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2390.
5. Cox, J.L., Sexton, P.S., Green, T.J., and Darmani, N.A. (1999). Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res. 9, 369-374.
6. DeClerck, Y.A., Imren, S., Montgomery, A.M., Mueller, B.M., Reisfeld, R.A., and Laug, W.E. (1997). Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425, 89-97.
7. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174.
8. Gomez, D.E., Alonso, D.F., Yoshiji, H., and Thorgeirsson, U.P. (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74, 111-122.
9. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E., and Iwata K. (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32.
10. Hewitt, R.E., Brown, K.E., Corcoran, M., and Stetler-Stevenson, W.G. (2000). Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line. J. Pathol. 192, 455-459.
11. Johansson, N., Ahonen, M., and Kahari, N.M. (2000). Matrix metalloproteinases in tumor invasion. Cell. Mol. Life Sci. 57, 5-15.
12. Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135.
13. Krol, J., Sato, S., Rettenberger, P., Assfalg-Machleidt, I., Schmitt, M., Magdolen, V., and Magdolen, U. (2003). Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol. Chem. 384, 1085-1096.
14. Lah, T.T., and Kos, J. (1998). Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. 379, 125-130.
15. Lutz, V., Reuning, U., Krüger, A., Luther, T., von Steinburg, S.P., Graeff, H., Schmitt, M., Wilhelm, O.G., and Magdolen, V. (2001). High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol. Chem. 382, 789-798.
16. Magdolen, U., Krol, J., Sato, S., Mueller, M.M., Sperl, S., Krüger, A., Schmitt, M., and Magdolen, V. (2002). Natural inhibitors of tumor-associated proteases. Radiol. Oncol. 36, 131-143.
17. 19-31 is a potent competetive antagonist of the interaction of urokinase type plasminogen activator with its receptor (CD87). Biol. Chem. 382, 1197-1205.
18. Muehlenweg, B., Sperl, S., Magdolen, V., Schmitt, M., and Harbeck, N. (2001). Interference with the urokinase plasminogen activator (uPA) system: a promising therapy concept for solid tumors. Exp. Opin. Biol. Ther. 1, 683-691.
19. Muehlenweg, B., Assfalg-Machleidt, I., Gil Parrado, S., Bürgle, M., Creutzburg, S., Schmitt, M., Auerswald, E.A., Machleidt, W., and Magdolen, V. (2000). A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. J. Biol. Chem. 275, 33562-33566.
20. Premzl A., Puizdar V., Zavasnik-Bergant V., Kopitar-Jerala N., Lah T.T., Katunuma N., Sloane B.F., Turk V., and Kos J. (2001). Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol. Chem. 382, 853-857.
21. Reuning, U., Sperl, S., Kopitz, C., Kessler, H., Krüger, A., Schmitt, M., and Magdolen, V. Urokinase-type plasminogen activator (uPA) and ist receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Design, in press.
22. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H., and Schmitt, M. (1998). Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13, 893-906.
23. Sato, S., Kopitz, C., Schmalix, W.A., Muehlenweg, B., Kessler, H., Schmitt, M., Krüger, A., and Magdolen, V. (2002). High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett. 528, 212-216.
24. Schmiedeberg, N., Schmitt, M., Rölz, C., Truffault, V., Sukopp, M., Bürgle, M., Wilhelm, O. G., Schmalix, W., Magdolen, V., and Kessler, H. (2002). Synthesis, solution structure, and biological evaluation of urokinase-type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem. 45, 4984-4994.
25. Sever, N., Filipic, M., Brzin, J., and Lah, T.T. (2002). Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro. Biol. Chem. 383, 839-842.
26. Stamenkovic, I. (2000). Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10, 415-433.
27. Stetler-Stevenson, W.G. (2001). The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg. Oncol. Clin. N. Am. 10, 383-392.
28. Yamashita, K., Suzuki, M., Iwata, H., Koike, T., Hamaguchi, M., Shinagawa, A., Noguchi, T., and Hayakawa, T. (1996). Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett. 396, 103-107.